Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of patients and cytokine responses

Patient no.	Stage^*	Ig class	Age	Debut^†	Treatment response^‡	IL-6 response^1-153	BMP-4 response^1-153	IL-6/BMP-4 interaction^1-153
1	IIIA	IgG	75	No	No	+	+	+
2	IIA	IgA	74	Yes	Yes	−	−	−
3	IIA	IgA	79	No	ND	−	−	−
4	IIA	IgD	48	Yes	Yes	−	−	−
5	IIIA	IgG	76	No	No	−	+	+
6	IIIA	IgG	60	No	No	−	−	−
7	IIIA	IgA	73	Yes	Yes	−	−	−
8	IA	IgG	84	No	Yes	−	−	−
9	IIA	IgA	76	Yes	Yes	+	+	+
10	IIA	IgA	70	Yes	Yes	−	−	−
11	IIIA	IgA	76	No	No	+	+	+
12	IIIA		51	No	No	−	−	−
13	IIIA	IgG	76	Yes	Yes	−	−	−

Patient no.	Stage^*	Ig class	Age	Debut^†	Treatment response^‡	IL-6 response^1-153	BMP-4 response^1-153	IL-6/BMP-4 interaction^1-153
1	IIIA	IgG	75	No	No	+	+	+
2	IIA	IgA	74	Yes	Yes	−	−	−
3	IIA	IgA	79	No	ND	−	−	−
4	IIA	IgD	48	Yes	Yes	−	−	−
5	IIIA	IgG	76	No	No	−	+	+
6	IIIA	IgG	60	No	No	−	−	−
7	IIIA	IgA	73	Yes	Yes	−	−	−
8	IA	IgG	84	No	Yes	−	−	−
9	IIA	IgA	76	Yes	Yes	+	+	+
10	IIA	IgA	70	Yes	Yes	−	−	−
11	IIIA	IgA	76	No	No	+	+	+
12	IIIA		51	No	No	−	−	−
13	IIIA	IgG	76	Yes	Yes	−	−	−

According to Durie and Salmon.60

†

Denotes whether primary cells were harvested at the time of diagnosis or not.

‡

Response to treatment with melphalan–prednisone or vincristine, doxorubicin, and dexamethasone regimens was defined as reduction of the M-component by 50% or more.

F1-153

Purified myeloma cells were incubated for 3 days with or without IL-6 (1 ng/mL) or BMP-4 (50 ng/mL), and cellular viability was determined. A positive response was defined as a 10% or greater absolute change in viability after BMP-4 or IL-6 stimulation compared with unstimulated cells. Interaction was defined to be present if the response of either cytokine was counteracted by ≥ 10% by the other. Patient 12 had nonsecretory myeloma.

ND, not determined.

View Large

This Feature Is Available To Subscribers Only